Phibro Animal Health Corporation (PAHC)
| Market Cap | 2.20B |
| Revenue (ttm) | 1.46B |
| Net Income (ttm) | 92.09M |
| Shares Out | 40.53M |
| EPS (ttm) | 2.26 |
| PE Ratio | 24.02 |
| Forward PE | 17.02 |
| Dividend | $0.48 (0.88%) |
| Ex-Dividend Date | Mar 4, 2026 |
| Volume | 508,767 |
| Open | 56.20 |
| Previous Close | 56.14 |
| Day's Range | 51.43 - 57.09 |
| 52-Week Range | 18.01 - 60.08 |
| Beta | 0.69 |
| Analysts | Hold |
| Price Target | 41.25 (-24.02%) |
| Earnings Date | May 6, 2026 |
About PAHC
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional ... [Read more]
Financial Performance
In fiscal year 2025, Phibro Animal Health's revenue was $1.30 billion, an increase of 27.37% compared to the previous year's $1.02 billion. Earnings were $48.26 million, an increase of 1897.68%.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for PAHC stock is "Hold." The 12-month stock price target is $41.25, which is a decrease of -24.02% from the latest price.
News
Phibro Animal Health Corporation Announces Regulatory Framework Change in Brazil for Antimicrobials
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) today announced expected implementation of a new regulatory framework governing the use of certain antimicrobials in Bra...
Phibro Animal Health Transcript: BofA Securities Animal Health Summit
Strong revenue and income growth were driven by the Zoetis MFA acquisition, robust vaccine and nutritional specialty performance, and positive market dynamics. Integration of the acquisition is nearly complete, with expanded geographic reach and enhanced customer offerings. Leadership transition will maintain strategic continuity.
Phibro Animal Health Corporation to Participate in Bank of America 2026 Virtual Animal Health Summit
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Bank of America 2026 Virtual Animal Health Summit. Chief Financial Officer, G...
Phibro Animal Health Earnings Call Transcript: Q2 2026
Q2 saw 21% sales and 41% EBITDA growth, led by animal health and MFA integration. Fiscal 2026 guidance was raised for sales, EBITDA, and net income, reflecting strong demand and operational momentum. Leadership transition and new product launches support future growth.
Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its second quarter ended December 31, 2025, and its up...
Phibro Animal Health Corporation Declares Quarterly Dividend
TEANECK, N.J.--(BUSINESS WIRE)--The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Cl...
Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its second quarter financial results on Wednesday, February 4, 2026, after the market closes. Phibro...
Phibro Animal Health Corporation Announces Leadership Transition
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (the “Company” or “Phibro”) today announced a leadership transition that will support the Company's continued growth and...
Phibro Animal Health Earnings Call Transcript: Q1 2026
Q1 2026 saw 40% sales growth and 102% adjusted EBITDA growth, driven by animal health and MFA integration. Fiscal 2026 guidance for EBITDA and net income was raised, with continued investment in innovation and companion animal expansion.
Phibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2025 and its upd...
Phibro Animal Health Corporation Announces National Launch of Restoris™ Piezoelectric Dental Gel for Dogs
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation is proud to announce the national launch of Restoris™ piezoelectric dental gel, a revolutionary dental gel designed to treat and suppor...
Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its first quarter financial results on Wednesday, November 5, 2025, after the market closes. Phibro ...
Phibro Animal Health Corporation Announces Licensing Agreement with Lighthouse Pharmaceuticals, Inc. for Innovative Periodontal Health Asset for Dogs
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC), a global leader in animal health and nutrition, today announced it has entered into a licensing agreement with Lighthou...
Phibro Animal Health Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Fiscal 2026 will see strong growth from the full-year Zoetis MFA portfolio, expanding vaccines and nutritional specialties, and the Phibro Forward initiative. Integration of the Zoetis deal has exceeded expectations, supporting margin gains and future investments. Vaccines and nutritional specialties are set to outpace overall market growth.
Phibro Animal Health Corporation to Participate at Morgan Stanley Annual Global Healthcare Conference
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. Chief Financial Officer, ...
Phibro Animal Health Earnings Call Transcript: Q4 2025
Q4 and FY2025 saw robust sales and EBITDA growth, led by Animal Health and the Zoetis MFA integration. FY2026 guidance projects continued double-digit growth, with Phibro Forward and full-year Zoetis contributions driving results.
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2025...
Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2025 Results
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2025 financial results on Wednesday, August 27, 2025, after the m...
Overlooked Stock: PAHC Taps 4-Year High
Phibro Animal Health (PAHC) rallied close to 7% after JPMorgan upgraded the stock and upped its price target. George Tsilis dives into the earnings and analyzes the financial health of the company.
Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost
JPMorgan upgraded Phibro Animal Health Corporation PAHC, citing strong execution following its $350 million acquisition of Zoetis' medicated feed additive and water-soluble product portfolio.
Phibro Animal Health Transcript: Stifel Jaws & Paws Conference 2025
A major acquisition expanded the product portfolio, geographic reach, and species coverage, driving strong sales and EBITDA growth. Integration has been smooth, with new opportunities in Europe and beef, and a focus on innovation and sustainability positioning the company for future growth.
Phibro Animal Health Corporation to Participate at Stifel Jaws & Paws Conference
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Stifel Jaws & Paws Conference. Chief Operating Officer, Larry Miller along wi...
Phibro Animal Health Earnings Call Transcript: Q3 2025
Q3 2025 saw 32% sales growth and 85% adjusted EBITDA increase, led by animal health and the Zoetis MFA integration. Fiscal 2025 guidance was raised for EBITDA and EPS, with tariff impacts expected to be manageable and strong cash flow supporting ongoing investments.
Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its third quarter ended March 31, 2025, and its update...
Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its third quarter financial results on Wednesday, May 7, 2025, after the market closes. Phibro manag...